A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer

European Urology

Volumn 69, Issue 5, 2016, Pages 855-862

  McConkey, David J ^a   Choi, Woonyoung ^a   Shen, Yu ^a   Lee, I Ling ^a   Porten, Sima ^a   Matin, Surena F ^a   Kamat, Ashish M ^a   Corn, Paul ^a   Millikan, Randall E ^b   Dinney, Colin ^a   Czerniak, Bogdan ^a   Siefker Radtke, Arlene O ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Essentia Health   (United States)

Author keywords

Basal; Bevacizumab; Dose dense methotrexate cisplatin; Gene expression profiling; Luminal; Neoadjuvant; p53; Subtype; Urothelial cancer

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOXORUBICIN; METHOTREXATE; VINBLASTINE; ANTINEOPLASTIC AGENT; PROTEIN P53; TRANSCRIPTOME;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CYSTECTOMY; DOSE DENSIFICATION; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE EXPRESSION PROFILING; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPONATREMIA; HYPOTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; NAUSEA; NEPHROURETERECTOMY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOSIS; TRANSURETHRAL RESECTION; UROGENITAL TRACT CANCER; VOMITING; ADJUVANT CHEMOTHERAPY; BLADDER TUMOR; BONE TUMOR; CLASSIFICATION; CLINICAL TRIAL; GENETICS; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECONDARY; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BONE NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYSTECTOMY; DOXORUBICIN; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TRANSCRIPTOME; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 84940703220     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.08.034     Document Type: Article

References (26)

1. H.B. Grossman, R.B. Natale, C.M. Tangen, and et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859 866
2. International Collaboration of Triallists International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 2011 2171 2177
3. C.N. Sternberg, J. Bellmunt, G. Sonpavde, and et al. ICUD-EAU International Consultation on Bladder Cancer 2012: chemotherapy for urothelial carcinoma - neoadjuvant and adjuvant settings Eur Urol 63 2013 58 66
4. Z.D. Reardon, S.G. Patel, H.B. Zaid, and et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides Eur Urol 67 2015 165 170
5. K. Inoue, J.W. Slaton, T. Karashima, and et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy Clin Cancer Res 6 2000 4866 4873
6. J.W. Slaton, R. Millikan, K. Inoue, and et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy J Urol 171 2004 570 574
7. C.N. Sternberg, P.H. de Mulder, J.H. Schornagel, and et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924 J Clin Oncol 19 2001 2638 2646
8. P. Bassi, G.D. Ferrante, N. Piazza, and et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort J Urol 161 1999 1494 1497
9. H. Wijkstrom, U. Norming, M. Lagerkvist, and et al. Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients Br J Urol 81 1998 686 691
10. R. Millikan, C. Dinney, D. Swanson, and et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC J Clin Oncol 19 2001 4005 4013
11. A.O. Siefker-Radtke, C.P. Dinney, Y. Shen, and et al. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results Cancer 119 2013 540 547
12. W. Choi, S. Porten, S. Kim, and et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy Cancer Cell 25 2014 152 165
13. J.S. Damrauer, K.A. Hoadley, D.D. Chism, and et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology Proc Natl Acad Sci U S A 111 2014 3110 3115
14. The Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma Nature 507 2014 315 322
15. S. Dudoit, J. Fridlyand, and T.P. Speed Comparison of discrimination methods for the classification of tumors using gene expression data J Am Stat Assoc 97 2002 77 87
16. G. Sjodahl, M. Lauss, K. Lovgren, and et al. A molecular taxonomy for urothelial carcinoma Clin Cancer Res 18 2012 3377 3386
17. S. Rebouissou, I. Bernard-Pierrot, A. de Reynies, and et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype Sci Transl Med 6 2014 244ra91
18. E.R. Plimack, J.H. Hoffman-Censits, R. Viterbo, and et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity J Clin Oncol 32 2014 1895 1901
19. T.K. Choueiri, S. Jacobus, J. Bellmunt, and et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates J Clin Oncol 32 2014 1889 1894
20. E. Scosyrev, B.W. Ely, E.M. Messing, and et al. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710) BJU Int 108 2011 693 699
21. C.M. Perou, T. Sorlie, M.B. Eisen, and et al. Molecular portraits of human breast tumours Nature 406 2000 747 752
22. A. Prat, M.J. Ellis, and C.M. Perou Practical implications of gene-expression-based assays for breast oncologists Nat Rev Clin Oncol 9 2012 48 57
23. P.L. Ho, A. Kurtova, and K.S. Chan Normal and neoplastic urothelial stem cells: getting to the root of the problem Nat Rev Urol 9 2012 583 594
24. W. Choi, J.B. Shah, M. Tran, and et al. p63 expression defines a lethal subset of muscle-invasive bladder cancers PloS One 7 2012 e30206
25. O. Karni-Schmidt, M. Castillo-Martin, T.H. Shen, and et al. Distinct expression profiles of p63 variants during uothelial development and bladder cancer progression Am J Pathol 178 2011 1350 1360
26. F.H. Groenendijk, J. de Jong, E.E. Fransen van de Putte, and et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy Eur Urol 69 2016 384 388